All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How has the treatment landscape of AML evolved in the last five years?

Featured:

Norbert VeyNorbert Vey

Dec 17, 2019


During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Norbert Vey, Institut Paoli-Calmettes, Marseilles, FR. We asked: How has the treatment landscape of acute myeloid leukemia evolved in the last five years?

Norbert Vey talks about the new drugs that have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. He discusses the new regimens that are being explored to treat patients, that historically had a dismal prognosis, in hope for better response and overall survival. He also explains the evolving diagnostic techniques (e.g. minimal residual disease status) that are being used to guide AML treatment pathway.

English

French

How has the treatment landscape of AML evolved in the last five years?

Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?